Abstract 1196P
Background
Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: a population-based study A short title: Regional lymph node metastasis risk factors for rectal neuroendocrine tumors Key words: regional lymph node metastasis, rectal neuroendocrine tumors, SEER, West China Hospital (WCH) databases, tumor size. Purpose: Risk factors for regional lymph node (r-LN) metastasis in rectal neuroendocrine tumors (R-NETs) are still undetermined. We aimed to explore risk factors for patients with r-LN metastatic R-NETs. Information on patients was obtained from the Surveillance, Epidemiology, and End Results (SEER) and West China Hospital (WCH) databases.
Methods
Patients diagnosed with R-NETs between January 2010 and December 2015 from the SEER database composed the construction cohort, while cases from the WCH database were used as the validation cohort. A novel nomogram was constructed to predict r-LN metastasis probability based on a logistic regression model. The performance of the nomogram was internally and externally validated using calibration curves and the concordance index (C-index).
Results
Multivariate logistic analysis identified four poor independent r-LN metastasis factors, including age (≥ 53), differentiation grade (> G1), T stage of primary tumor (> T1) and tumor size (> 1 cm), which we selected as the four risk predictors for nomogram construction. In the internal validation and external validation, the C-index in the internal validation set and the external validation set were 0.968 and 0.877, respectively. The nomogram model was well calibrated, and the ROC curves verified the superiority of our model for clinical usefulness. In addition, the nomogram classification could more accurately differentiate risk subgroups and improve the discrimination of R-NET prognosis.
Conclusions
We developed and validated a prediction risk model of r-LN metastasis for patients with R-NETs. The novel nomogram is a reliable tool to predict the risk of r-LN metastasis, which may assist clinicians in identifying high-risk patients and devising individual treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1119P - Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Presenter: Teresa Amaral
Session: Poster session 13
1120P - Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Presenter: Robert Stassen
Session: Poster session 13
1121P - Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1122P - Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?
Presenter: Maria Menezes
Session: Poster session 13
1123P - Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
Presenter: Mark Schuiveling
Session: Poster session 13
1124P - IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis
Presenter: Domenico Mallardo
Session: Poster session 13
1125P - Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy
Presenter: Benjamin Fairfax
Session: Poster session 13
1126P - REtrospective Study of definitive therapy for head and neck mUcosal MElanoma: The RESUME study
Presenter: Motoo Nomura
Session: Poster session 13
1127P - Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Presenter: James Pham
Session: Poster session 13
1128P - A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Presenter: Sapna Patel
Session: Poster session 13